Prostate Cancer Management: Future Directions in Care
Closing out their discussion on the management of prostate cancer, panelists consider remaining unmet needs and future directions in care.
Results of the VISION Trial and Real-World Use of 177Lu-PSMA-617 in mCRPC
Reflections on results of the VISION trial, which utilized 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer.
Metastatic CRPC: Clinical Pearls and Practical Advice
Highlighting ongoing clinical trials in prostate cancer, experts share practical advice on optimal treatment strategies for community physicians.
Addressing Bone and Visceral Metastases in Metastatic CRPC
A broader perspective on the management of bone and visceral metastases in metastatic CRPC given the current treatment landscape.
Role of 177Lu-PSMA-617 in mCRPC and Bone Metastases
Shifting their focus to 177Lu-PSMA-617 in metastatic CRPC, expert panelists consider its role in sequencing therapy and managing bone metastases.
Emerging Targeted Therapies in mCRPC
Before closing out their discussion, experts review novel targeted agents under investigation in metastatic CRPC.
Defining Unmet Needs in the Management of mCRPC
Experts share insight on the greatest unmet needs in treating patients with metastatic castration-resistant prostate cancer.
Selecting Among Novel Imaging Options in Metastatic CRPC
A brief discussion on how to select and apply novel imaging strategies in patients with metastatic castration-resistant prostate cancer.
Metastatic CRPC: Utility of Imaging as a Biomarker
Shared insight on the role of imaging as a phenotypic biomarker in patients being treated for metastatic castration-resistant prostate cancer.
Ongoing PSMA-Targeted Radioligand Trials in mCRPC
Andrew J. Armstrong, MD, MSc, breaks down ongoing prostate cancer clinical trials looking at targeted radioligand therapies.
Metastatic CRPC: Considerations for Radiotherapy
Oliver Sartor, MD, considers the respective roles of Lu-PSMA-617 and radium-223 as radiotherapy in the setting of mCRPC.
DNA Alterations and Selection of PARP Inhibitors in mCRPC
Expert perspectives on how DNA alterations may inform the selection and use of PARP inhibitors in metastatic CRPC.
Overview of Therapy for mCRPC: PARP Inhibitors
A broad overview of the armamentarium for metastatic CRPC followed by detailed discussion on the role of PARP inhibitors in this setting.
Potential Role of Lu-PSMA-617 in mCRPC
Expert perspectives on where Lu-PSMA-617 therapy may fit into the treatment paradigm for metastatic castration-resistant prostate cancer.
VISION Trial: Lu-PSMA-617 in mCRPC
A comprehensive review of the design and results of VISION, which analyzed Lu-PSMA-617 therapy in patients with mCRPC.
Interpreting Data From the ARASENS Trial in Metastatic HSPC
Comprehensive insight on results from the ARASENS trial and how panelists will be incorporating what was learned into real-world clinical practice.
Selecting Optimal Therapy for mHSPC: Design of the ARASENS Trial
Focusing on treatment selection factors in metastatic HSPC, panelists consider how the ARASENS trial redefined treatment approaches.
Role of Radium-223 in Treating mCRPC
Expert Scott Tagawa, MD, MS, FACP, details the role of radium-223 in treating metastatic CRPC and highlights real-world experiences.
Patient Factors in Selecting Therapy for mCRPC
Shared insight on the key factors that play into the selection of therapy for patients with metastatic castration-resistant prostate cancer.
Role of Micronized Abiraterone in Metastatic HSPC
Shared insight on the role of micronized abiraterone in metastatic HSPC and how it may be utilized in practice.
Overview of Treatment for Metastatic HSPC
Expert perspectives on metastatic hormone-sensitive prostate cancer and the current state of the treatment armamentarium.
Monitoring Strategies in Nonmetastatic CRPC
A brief discussion on best practices in monitoring patients on therapy for nonmetastatic castration-resistant prostate cancer [nmCRPC].
Phenotypic Biomarkers in the Management of Prostate Cancer
Expert perspectives on phenotypic biomarkers in prostate cancer and their role in comparison to genotypic biomarkers.
Factors in Selecting Novel AR-Targeted Therapy for Nonmetastatic CRPC
Comprehensive insight on selecting androgen receptor–targeted therapy for patients with nonmetastatic castration-resistant prostate cancer.
Background on Prostate Cancer and Biomarker Testing
Broad discussion on the role of biomarker testing in prostate cancer, particularly how it has helped to inform therapy selection and patient management.
Evolving Treatment Landscape of Nonmetastatic CRPC
Focusing on nonmetastatic castration-resistant prostate cancer, panelists review the current treatment armamentarium and shared decisionmaking.
Future Outlook on the Management of Metastatic Urothelial Cancer
Drs Arlene O. Siefker-Radtke and Scott T. Tagawa consider how the urology field will likely advance with more interest in genomic profiling in metastatic urothelial cancer and novel therapies in the pipeline.
Mitigating FGFR Inhibitor TRAEs in Metastatic Urothelial Cancer
An overview of adverse events commonly associated with FGFR-targeted therapies such as erdafitinib.
FGFR-Targeted Therapy for Metastatic Urothelial Cancer
Strategies that can be used to counsel patients on molecular testing for FGFR mutations and what to expect from treatment with erdafitinib.
Repeat Molecular Testing in Metastatic Urothelial Cancer
Current recommendations for repeat testing in patients with relapsed metastatic urothelial cancer.
Dr Graff on the Relation Between ctDNA Positivity and Disease Recurrence in HR+/HER2– Breast Cancer
Dr Damodaran on Futibatinib Plus Fulvestrant in FGFR1-Amplified HR+/HER2– Breast Cancer
Trastuzumab Deruxtecan Plus Endocrine Therapy Demonstrates Antitumor Activity in HER2-Low/HR+ Metastatic Breast Cancer
T-DXd Yields Early Activity in HER2+/HER2-Low Breast Cancer With Leptomeningeal Carcinomatosis
2 Clarke Drive Cranbury, NJ 08512